Determinants of the maternal 25-hydroxyvitamin D response to vitamin D supplementation during pregnancy

Moon, Rebecca J, Harvey, Nicholas C, Cooper, Cyrus, D'Angelo, Stefania, Crozier, Sarah R, Inskip, Hazel M, Schoenmakers, Inez, Prentice, Ann, Arden, Nigel K, Bishop, Nicholas J, Carr, Andrew, Dennison, Elaine M, Eastell, Richard, Fraser, Robert, Gandhi, Saurabh V, Godfrey, Keith M, Kennedy, Stephen, Mughal, M Zulf, Papageorghiou, Aris T, Reid, David M, Robinson, Sian M and Javaid, M Kassim and the MAVIDOS Trial Group (2016) Determinants of the maternal 25-hydroxyvitamin D response to vitamin D supplementation during pregnancy. Journal of Clinical Endocrinology & Metabolism, 101 (12). 5012–5020. ISSN 0021-972X

[thumbnail of Published manuscript]
PDF (Published manuscript) - Published Version
Available under License Creative Commons Attribution.

Download (510kB) | Preview


Context: Current approaches to antenatal vitamin D supplementation do not account for inter-individual differences in 25-hydroxyvitamin D [25(OH)D] response.  Objective: We assessed which maternal and environmental characteristics were associated with 25-hydroxyvitamin D [25(OH)D] following supplementation with cholecalciferol.  Design: Within-randomisation-group analysis of participants in the MAVIDOS trial of vitamin Dsupplementation in pregnancy.  Setting: Hospital antenatal clinics  Participants: 829 pregnant women (422 placebo, 407 cholecalciferol). At 14 and 34 weeks’ gestation, maternal anthropometry, health and lifestyle were assessed and 25(OH)D measured. Compliance was determined using pill counts at 19 and 34 weeks.  Interventions: 1000IU/day cholecalciferol or matched placebo from 14 weeks’ gestation until delivery.  Main outcome measure: 25-(OH)D at 34 weeks, measured in a single batch (Diasorin Liaison).   Results: 25(OH)D at 34 weeks’ gestation was higher in the women randomised to vitamin D [mean(SD): 67.7 (21.3) nmol/l] compared with placebo [43.1 (22.5) nmol/l, p<0.001]. In womenrandomised to cholecalciferol, higher pregnancy weight gain from 14 to 34 weeks’ gestation[kg] (β=-0.81 (95%CI -1.39, -0.22)), lower compliance with study medication [%] (β=-0.28 (-0.072, -0.48)), lower early pregnancy 25(OH)D [nmol/l] (β=0.28 (0.16, 0.40)) and delivery inthe winter vs the summer (β=-10.5 (-6.4, -14.6)) were independently associated with lower25(OH)D at 34 weeks’ gestation.  Conclusions: Women who gained more weight during pregnancy, had lower 25(OH)D in early pregnancy and delivered in winter achieved a lower 25(OH)D in late pregnancy when supplementedwith 1000 IU/day cholecalciferol. Future studies should aim to determine appropriate dosesto enable consistent repletion of 25-hydroxyvitamin D during pregnancy.

Item Type: Article
Additional Information: This article has been published under the terms of the Creative Commons Attribution License (CC-BY;, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s).
Uncontrolled Keywords: vitamin d,pregnancy,osteoporosis,epidemiology,supplementation
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Musculoskeletal Medicine
Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine
Related URLs:
Depositing User: Pure Connector
Date Deposited: 26 Oct 2016 12:00
Last Modified: 03 Nov 2022 15:41
DOI: 10.1210/jc.2016-2869


Downloads per month over past year

Actions (login required)

View Item View Item